Data-Centric Organoid Services For Predictive Drug Response And Next-Generation Oncology Research

By Seahee Kim, Director of Organoids Technology

With first-in-human trial success rates below 10%, the limitations of conventional preclinical models remain a persistent challenge in oncology drug development. Patient-derived organoids have emerged as a practical response, but their translational utility depends on more than generating 3D tumor models. It requires connecting functional screening data to the molecular and clinical context that explains what the data mean.

This whitepaper, authored by Seahee Kim, PhD, Director of Organoids Technology, examines how integrating high-throughput and high-content screening, multi-omics analysis, immune co-culture systems, and annotated clinical records can transform organoid platforms from experimental tools into sources of predictive insight. The paper also presents data from colorectal cancer organoid studies demonstrating 94% retention of tumor genetic alterations and drug-sensitivity profiles consistent with matched patient outcomes.

Explore the full whitepaper to see how these capabilities come together in practice.